- Home
- VTRS vs MBLY Comparison
VTRS vs MBLY Comparison
Compare VTRS & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTRS
- MBLY
- Stock Information
- Founded
- VTRS 1961
- MBLY 1999
- Country
- VTRS United States
- MBLY Israel
- Employees
- VTRS N/A
- MBLY N/A
- Industry
- VTRS Medicinal Chemicals and Botanical Products
- MBLY Computer Software: Prepackaged Software
- Sector
- VTRS Health Care
- MBLY Technology
- Exchange
- VTRS Nasdaq
- MBLY Nasdaq
- Market Cap
- VTRS 12.2B
- MBLY 10.9B
- IPO Year
- VTRS N/A
- MBLY 2022
- Fundamental
- Price
- VTRS $10.76
- MBLY $12.32
- Analyst Decision
- VTRS Hold
- MBLY Buy
- Analyst Count
- VTRS 6
- MBLY 17
- Target Price
- VTRS $11.17
- MBLY $19.44
- AVG Volume (30 Days)
- VTRS 9.4M
- MBLY 4.7M
- Earning Date
- VTRS 11-06-2025
- MBLY 10-23-2025
- Dividend Yield
- VTRS 4.48%
- MBLY N/A
- EPS Growth
- VTRS N/A
- MBLY N/A
- EPS
- VTRS N/A
- MBLY N/A
- Revenue
- VTRS $14,124,400,000.00
- MBLY $1,938,000,000.00
- Revenue This Year
- VTRS N/A
- MBLY $15.48
- Revenue Next Year
- VTRS $1.61
- MBLY $7.59
- P/E Ratio
- VTRS N/A
- MBLY N/A
- Revenue Growth
- VTRS N/A
- MBLY 7.61
- 52 Week Low
- VTRS $6.85
- MBLY $11.58
- 52 Week High
- VTRS $13.55
- MBLY $22.51
- Technical
- Relative Strength Index (RSI)
- VTRS 57.42
- MBLY 36.27
- Support Level
- VTRS $9.92
- MBLY $12.26
- Resistance Level
- VTRS $11.28
- MBLY $13.10
- Average True Range (ATR)
- VTRS 0.35
- MBLY 0.44
- MACD
- VTRS 0.04
- MBLY -0.05
- Stochastic Oscillator
- VTRS 61.43
- MBLY 11.39
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.